Genetically modified mice are important models for evaluation of potential gene therapies for human diseases. However, their small size often precludes the use of clinically feasible methods for vector delivery, therefore, alternative methods must be used. We have developed a gel-based method for delivery of recombinant adeno-associated virus vectors to the mouse diaphragm, an important target organ for many myopathic diseases. We hypothesized that delivery of vectors in a viscous solution would increase transduction by providing a longer exposure time to target cells. We demonstrate that gel-mediated delivery of rAAV serotypes 1, 2, and 5 results in higher transduction efficiencies than free vectors alone when administered in vivo to mouse diaphragms. We further establish greater tropism of rAAV1 vectors for the diaphragm compared to serotypes 2 and 5. This report describes a novel method for efficient delivery of rAAV vectors to the mouse diaphragm and is the first demonstration of gene transfer to the diaphragm using recombinant adeno-associated virus vectors.
INTRODUCTION
Mouse models of human disease provide invaluable opportunities to evaluate the potential efficacy of candidate therapies. Gene therapy strategies in particular have benefited enormously from the profusion of knockout and transgenic mice that recapitulate the genetic and pathophysiologic features of human diseases. Congenital myopathies, including the muscular dystrophies, have been widely investigated as targets for gene therapy interventions, and the diaphragm is often cited as one of the important target organs for functional correction [1] .
The mouse diaphragm presents unique challenges in terms of delivery of therapeutic agents due to its small size and thickness, which preclude direct injection into the muscle. Intravenous or intra-arterial delivery of vectors may be effective alternatives and are currently under investigation [2, 3] ; however, isolation of blood vessels that specifically perfuse the diaphragm is also difficult in the mouse. Systemic delivery of vectors may eventually require the application of capsid-based targeting methods that have recently been reported [4 -10] .
Adeno-associated virus is a single-stranded DNA-containing, nonpathogenic human parvovirus that is being widely investigated as a therapeutic vector for a host of muscle disorders [11 -14] . Six serotypes of the virus (AAV1 -6) were originally described, and two more have recently been identified in rhesus macaques [15] . Recombinant adeno-associated virus (rAAV) vectors have been developed in which the rep and cap open reading frames of the wild-type virus have been completely replaced by a therapeutic or reporter gene, retaining only the characteristic inverted terminal repeats, the sole cis-acting elements required for virus packaging. Using helper plasmids expressing various combinations of the AAV2 rep and AAV1, 2, and 5 cap genes, our group and others have demonstrated efficient cross-packaging of AAV2 genomes into particles containing the AAV1, 2, or 5 capsid protein [16 -19] . The various serotype vectors have demonstrated distinct tropisms for different tissue types in vivo, due in part to their putative cell surface receptors. Although several reports have indicated that rAAV1 vectors efficiently transduce skeletal muscle in general [20 -23] , no study to date has reported which of the serotypes, if any, might transduce the diaphragm in particular.
The aim of this study is to provide a safe, effective, and uniform method for delivery of recombinant adeno-associated virus vectors to the mouse diaphragm to evaluate their potential as therapeutic agents. We evaluate the ability of rAAV serotypes 1, 2, and 5 to transduce the mouse diaphragm. We further describe the application of a gel-based delivery method and demonstrate its utility for delivery of rAAV1, 2, and 5 to the mouse diaphragm. Our results are the first to demonstrate efficient, uniform expression of a transgene in the murine diaphragm using rAAV vectors. Finally, we assess the utility of this method using a mouse model (Gaa
) of glycogen storage disease type II (GSDII) [24] , an autosomal recessive disorder that is characterized by respiratory insufficiency secondary to diaphragmatic weakness in affected juveniles [25] . We believe the method we describe may have broad applicability for delivery of gene therapy vectors not only to the diaphragm but perhaps to other tissues as well.
RESULTS

Efficiency of Transduction Using Gel-Based Delivery of rAAV in Vivo
We investigated the efficiency of rAAV delivery using the gel-based method compared to free virus delivery using h-galactosidase as a reporter gene (Fig. 1A) . Direct particle-to-particle comparisons of histochemistry from free-virus-treated animals (left column) versus gel-based delivery (right column) indicate an increased efficiency of transduction for all serotypes using the latter method. Quantitative analysis of 11 particles of rAAV-hgal, with virus either applied directly to the diaphragm or applied using the gel-based method. The animals were sacrificed 6 weeks later and tissues were collected and assayed for hgalactosidase activity. (A) Representative histochemical (X-gal) stained diaphragm segments from treated animals. Each row corresponds to the respective serotype into which the recombinant vector genome was packaged (AAV1, 2, or 5). The columns represent application of free virus (left) or virusgel suspension (right) to the abdominal surface of the diaphragms. Note the intense blue staining in both columns for vector virions packaged using the rAAV1 capsid (top row), with increased intensity using the gel-based method (top row, right). (B) Quantitative assay of h-galactosidase activity from the same animals. The bars represent mean F SEM GAA activity for three mice in each group. tissue lysates from these animals using the GalactoStar enzymatic assay for h-galactosidase confirms these results (Fig. 1B) . Activities for subjects treated with gel -vector suspensions had higher activities for all three serotypes.
Varying Tropisms of rAAV Serotypes 1, 2, and 5 for Diaphragm Muscle in Vivo The results from Figs. 1A and 1B also indicate a distinct gradient of tropism for mouse diaphragm among the three tested serotypes. Qualitatively, rAAV1 vectors led to the most intense staining under both the free virus and the gel-based conditions. Differences between rAAV2 and rAAV5 were hard to distinguish in the free virus case due to the low levels of transduction for both vectors, but the gel-mediated subjects demonstrated a clear preference for rAAV2 compared to rAAV5. These results are further verified in Fig. 1B , which indicates higher levels of enzyme activity for rAAV2 gel suspensions compared to rAAV5. Taken together, the results of histochemical staining and enzymatic activity indicate (1) a substantial increase in viral transduction using a physical delivery system and (2) a clearly enhanced mouse diaphragm tropism for rAAV1 and a potentially important difference between rAAV2 and rAAV5.
Gel-Based Delivery of rAAV1-GAA Results in Biochemical Correction of Diaphragms in Gaa
À/À Mice Having demonstrated increased transduction of the mouse diaphragm using the gel-based method, we assessed the ability of this method to restore enzymatic activity in a mouse model of glycogen storage disorder type II (GSDII; MIM 232300), a lysosomal glycogen storage disease caused by a lack or deficiency of the lysosomal enzyme acid a-glucosidase (GAA; EC 3.2.1.20). The mouse model of this disease stores glycogen in all tissues, with significant pathologies in the heart and skeletal muscle [24] . We have previously characterized the use of rAAV vectors to restore enzymatic and functional activity in skeletal and cardiac muscle in these mice [20] . Coupled with our new findings using a gel-based delivery method, we hypothesized that gel-based delivery of rAAV1-GAA would be able to restore GAA activity in Gaa À/À diaphragms and, in turn, reverse lysosomal glycogen accumulation.
Using rAAV1-GAA vectors, we found increases in diaphragmatic transduction in Gaa À/À mice similar to those seen in control mice with h-galactosidase vector. GAA enzymatic activities were restored to 50% of wild type with free vector and were further increased to 120% of normal levels using a vector -gel suspension ( Fig. 2A) . These activities had a profound effect on glycogen storage, as assessed by periodic acid -Schiff's reagent (PAS) staining (Fig. 2B) . Dark pink vacuoles, indicative of stored glycogen, are observed in free-vector-treated diaphragms from Gaa À/À mice, whereas a near-complete reversal of glycogen accumulation from diaphragms is seen in geltreated mice.
Biodistribution of rAAV Genomes after Gel-Based Delivery
Since a secondary advantage of physical delivery systems may be the ability to restrict viral spread, we also sought to determine which tissues endocytosed our viral vectors after gel-based delivery. To this end, we harvested various tissues from rAAV1-hgal gel-treated mice and extracted total cellular DNA. Using a nested PCR technique, we amplified a portion of the h-galactosidase gene from vector genomes (Fig. 3) . As expected, vector genomes could be detected in treated diaphragms. We could not detect vector genomes in any other tissue examined (including sections of the peritoneal wall and liver adjacent to the diaphragm); however, it is possible that more sensitive detection methods
Adult Gaa À/À mice were treated with 1Â10 11 particles of rAAV1-GAA in the quadriceps muscle. Wild-type (WT) and untreated Gaa À/À (MOCK) mice were used as controls. Muscle tissues were isolated at 6 weeks after treatment and assayed for GAA activity. The bars represent mean F SEM GAA activity for three mice in each group. (B) Representative sections from free vector-(left) and gel-based vector-treated (right) Gaa À/À mouse diaphragms, stained for glycogen using periodic acid -Schiff's reagent. Glycogen-containing vacuoles and regions acquire a pink stain using this technique.
(such as real-time PCR) would detect trace amounts of vector genomes.
DISCUSSION
Transduction events for recombinant adeno-associated viruses can be separated into five general stages: (1) binding and entry (endocytosis), (2) endosomal processing and escape, (3) transcytosis, (4) nuclear import and uncoating, and (5) genome conversion, including second-strand synthesis (or alternatively self-complementation), followed by genome concatemerization and/or integration into the host chromosome. We have sought in this report to enhance the first step of this process using a physical method to prolong viral dwell time-we expect to increase the efficiency of transduction by providing longer viral particle exposure times to receptors on target tissues. Carrier molecules and delivery agents have been used extensively for gene therapy applications, particularly for nonviral gene delivery. With regard to viral vectors, recombinant adenoviruses have been used in concert with a variety of agents to increase or prolong bioavailability, thereby enhancing the efficiency of delivery. March and colleagues [26] reported the use of poloxamer 407, a hydrogel that exhibits potentially useful, thermoreversible gelation, enabling formulation at low temperature with subsequent hardening to a robust gel at room and physiologic temperatures. They demonstrated increased transduction of vascular smooth muscle cells in vitro, with similar findings reported in vivo by Van Belle et al. [27] . Unfortunately, poloxamers have recently been shown to have adverse effects on adeno-associated virus stability [28] . Likewise, thixotropic solutions have also shown promise for enhancing adenovirus-mediated transduction of airway epithelia [29] . Several other promising agents have also been effectively used with adenovirus vectors, including h-cyclodextrins, surfactants, and collagen-or gelatin-based matrices.
While extensive testing of potential adenovirus formulations has been reported, few similar studies are extant for adeno-associated viruses. Most of the available literature describes formulations that increase stability for storage or purification, but few reports address the need for augmented physical delivery of viral particles in vivo. We have previously described the use of microsphere-conjugated rAAV for systemic delivery of viral vectors, in which we were able to increase significantly the transduction efficiency in target tissue beds in vivo by increasing vector dwell time [30] . Similarly, a number of groups are currently developing capsid-modified rAAV vectors to target specific vascular beds upon systemic delivery. To date, however, we are unaware of other examples of physical delivery agents or methods to improve rAAV delivery to tissue surfaces, such as skin, blood vessel adventitia, or diaphragm. The presented strategy for diaphragmatic delivery of rAAV relies on retention of vector on the peritoneal surface of the diaphragm. Local delivery using this strategy is clinically achievable by endoscopic delivery and has the added benefit of reduced risk associated with systemic vascular delivery. While the method that we describe has been specifically applied to the murine diaphragm, we anticipate that this formulation or similar ones will have broad utility for a variety of tissues, both for preclinical proof-of-principle studies in animal models and for eventual clinical applications (e.g., topical applications for wound healing).
Previous studies of gene transfer to the diaphragm in rodents have been attempted via delivery of nonviral or adenoviral gene transfer vectors. Liu et al. recently described a method for systemic delivery of plasmid DNA carrying the full-length dystrophin gene with subsequent targeting to the diaphragm in mdx mice [3] , a mouse strain with X-linked muscular dystrophy that mimics the diaphragmatic degeneration observed in Duchenne muscular dystrophy [31] . In that study, which used no carrier molecules, plasmid DNA was delivered intravenously via tail vein followed by transient (8-s) occlusion of the vena cava at the level of the diaphragm. High levels of gene expression were measured in diaphragm homogenates the next day and for 180 days [3] , implicating dwell time as potentially the most significant determinant of successful gene transfer to the diaphragm with naked DNA. Two reports [32, 33] , by Petrof, Yang, and colleagues, also indicated successful direct injection of recombinant adenoviruses carrying a mini-dystrophin gene to the diaphragms of mdx mice. Both studies demonstrated high levels of expression focally, presumably due to the delivery method. Transient gene expression, due to vector-
Biodistribution of rAAV1 vector genomes after gel-based delivery. We used nested PCR to amplify AAV genomes carrying the h-galactosidase gene after isolating tissues from gel-based rAAV1-hgal-treated mice. Total cellular DNA was extracted and AAV genomes were amplified using primers specific for the hgal transgene. The expected product is 333 bp, and the positive control is the vector plasmid that was used to package the rAAV particles.
related, dose-dependent inflammation, made assessment of the uniformity of gene expression difficult, but even with focal expression the authors observed measurable improvements in contractile function. More recently, Sakamoto et al. have developed an mdx strain that is transgenic for a micro-dystrophin construct [34] , which is within the packaging capacity of rAAV. We are currently investigating whether the combination of the dystrophin-associated complex transgenes and gel-based delivery of rAAV will lead to uniform phenotypic correction in diaphragms of dystrophic mice.
Comparisons of rAAV serotype tropisms for skeletal muscle have already been reported [20 -23] . Several recombinant AAV vectors based on alternative serotypes have demonstrated greater transduction efficiencies in skeletal muscle than serotype 2. In particular, several reports have shown nearly 1 log greater expression of a variety of transgenes when packaged in rAAV1 capsids compared to rAAV2. Similar findings have been reported with rAAV6, although this serotype has not been as widely studied [23, 35] . Clear differences in serotype tropism were observed between rAAV1 and the other two serotypes in the context of gel-based delivery and free virus administration, with significant differences observed between rAAV1 and rAAV5 (P<0.1). We note that the eightfold overexpression of GAA in Gaa-deficient diaphragms after delivery of free rAAV1-GAA compared to serotype 2 (Fig. 1B, AAV1 Free vs AAV2 Free) is nearly identical to our prior observations after direct intramuscular administration of the same two vectors in tibialis anterior muscles of Gaa À/À mice [20] , indicating a conserved rAAV1 tropism for skeletal muscle.
MATERIALS AND METHODS
Packaging and purification of recombinant AAV1, 2, and 5 vectors. The recombinant AAV2 plasmids pAAV-lacZ [12] and p43.2-GAA [20] have been described previously. Recombinant AAV vectors were generated, purified, and titered at the University of Florida Powell Gene Therapy Center Vector Core Lab as previously described [18] . Recombinant AAV particles based on serotypes 1, 2, and 5 were produced using pAAV-lacZ, whereas only rAAV1 particles (rAAV1-GAA) were packaged with p43.2-GAA.
Vector/vehicle preparation. A sterile, bacteriostatic, water-soluble, glycerin-based gel was used as a vehicle for vector application to the diaphragm (K-Y Sterile; Johnson & Johnson Medical, Arlington, TX, USA). Individual doses of virus were diluted in sterile phosphate buffered saline (PBS) for a total volume of 10 Al and then added to 150 Al of gel in a 2-ml microcentrifuge tube. The virus -vehicle suspension was vortexed for 1 min and then centrifuged for one minute at maximum speed. Free virus was diluted in sterile PBS for a total volume of 50 Al.
In vivo delivery. All animal studies were performed in accordance with the guidelines of the University of Florida Institutional Animal Care and Use Committee. Adult 129X1ÂC57BL/6 (wild type) or Gaa À/À mice [24] were anesthetized using 2% isoflurane and restrained supine on a warmed operating surface. In a sterile field, after reaching a surgical plane of anesthesia, a midline incision was made through the skin extending from the xyphoid process to the suprapubic region. An incision was made through the abdominal wall following the linea alba. The abdominal walls were retracted laterally, the gall bladder was carefully separated from the rib cage, and the liver was carefully retracted from the diaphragm using sterile cotton swabs. While the xyphoid was lifted, free virus or virus mixed with vehicle was applied directly to the abdominal surface of the diaphragm. Free virus was applied using a pipet. To facilitate application of the gel to the diaphragm, a 22-gauge needle was used to puncture the bottom of the microcentrifuge tube and a plunger from a 3-cc syringe was used to force the gel through the hole and onto the diaphragm surface (Fig. 4) . In some cases, a cottontipped applicator was used to ensure even spread over the entire diaphragm. After 5 min the abdominal muscles were sutured and the skin was closed. Subcutaneous ampicillin (20 -100 mg/kg) and buprenorphine (0.1 mg/kg) were administered prior to removing the animal from anesthesia.
Assays of b-galactosidase and GAA enzymatic activity. Six weeks after the surgical procedure and gene delivery, tissue lysates were assayed for enzyme activity using the Galacto-Star chemiluminescence reporter gene assay system (Tropix, Inc., Bedford, MA, USA). Protein concentrations for tissue lysates were determined using the Bio-Rad DC protein assay kit (BioRad, Hercules, CA, USA). For rAAV1-GAA-treated animals, enzymatic activity assays for GAA were performed 6 weeks after vector delivery as described previously [20] . Tissue homogenates were assayed for GAA activity by measuring the cleavage of the synthetic substrate 4-methylumbelliferyl-a-D-glucoside (Sigma M9766; Sigma -Aldrich, St. Louis, MO, USA) after incubation for 1 h at 37jC. Successful cleavage yielded a fluorescent product that emits at 448 nm, as measured with an FLx800 microplate fluorescence reader (Bio-Tek Instruments, Winooski, VT, USA). Protein concentration was measured as described above. Data are represented as nanomoles of substrate cleaved in 1 h per milligram of total protein in the lysate.
Histological assessment of glycogen clearance. Segments of treated and untreated diaphragm were fixed overnight in 2% glutaraldehyde in PBS, embedded in Epon, sectioned, and stained with PAS by standard methods [24] .
FIG. 4.
Gel-based delivery preparation. (Top) rAAV vectors are mixed in a 2-mL microcentrifuge tube and then centrifuged briefly. (Middle) The tube is punctured using a 22-gauge needle, creating an aperture through which the virus -gel suspension can be propelled. (Bottom) A plunger from a standard 3-cc syringe is used to push the vector from the tube, enabling its application to the diaphragmatic surface. The oblique, bottom surface of the microcentrifuge tube is used to distribute the vector -gel suspension evenly on the surface.
Biodistribution of vector genomes. Tissues were removed using sterile instruments and snap-frozen in liquid nitrogen. Total cellular DNA was extracted from tissue homogenates using a Qiagen DNeasy kit per the manufacturer's instructions (Qiagen, Valencia, CA, USA). Nested PCR was performed as follows: 1.5 Ag total DNA was used as a template for the initial PCR amplification using the sense primer 5V-AGCTGGCGTAA-TAGCGAAGA-3V and reverse primer 5V-CGCGTCTCTCCAGGTAGCGAA-3V, yielding a 1486-bp product. The PCR product was purified using the Qiagen MinElute PCR purification kit per the manufacturer's instructions, followed by PCR amplification using the sense primer 5V-CGGTGA-TGGTGCTGCGTTGGAG-3V and reverse primer 5V-TCGACGTTCAGACG-TAGTGT-3V, resulting in a final product of 333 bp. All reactions were performed under the following conditions: hot start denaturation at 94jC for 5 min, followed by 30 cycles of denaturation at 94jC for 1 min, annealing at 62jC for 1 min, and extension at 72jC for 2 min. Products were electrophoresed and analyzed using a 2% agarose gel.
